ecancer

ecancer.org

ecancer is a UK charity which provides accessible, high-quality educational content, free to the global oncology community. Our mission is to raise the standards of care for cancer patients across the world through education.

 

ecancer
J

EHA 2021 Update on 1L Ibrutinib + Venetoclax for CLL/SLL: Primary Analysis of the CAPTIVATE Study

By ecancer FEATURING John Allan
By ecancer FEATURING John Allan
16 views
September 6, 2021
0 Comments
Login to view comments. Click here to Login

Featured Video

20:00
Exelixis

Child-Pugh Classification and its Role in Treatment Decisions in Pat…

Feat. P. Gholam

Featured Video

21:09
Exelixis

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam
Leukemia
07:33
ecancer

Epitope Editing Enables Targeted Immunotherapy of AML

Feat. G. Casirati
04:14
ecancer

ALPINE: A Randomized Phase 3 Study of Zanubrutinib vs. Ibrutinib for…

Feat. J. Brown
04:55
ecancer

First Results of a Head-to-Head Trial of Acalabrutinib vs. Ibrutinib…

Feat. J. Byrd
04:36
ecancer

Safety & Efficacy of Asciminib for Heavily Pretreated Patients W…

Feat. M. Mauro
10:41
ecancer

EHA 2021 Update on 1L Ibrutinib + Venetoclax for CLL/SLL: Primary An…

Feat. J. Allan
05:12
ecancer

EHA 2021 Update on Venetoclax + Obinutuzumab in Untreated CLL: 4-yea…

Feat. O. Al-Sawaf
07:02
ecancer

EHA 2021 Primary Analysis From the OPTIC Trial on CP-CML: A Dose-Ran…

Feat. J. Cortés
07:36
ecancer

EHA 2021 Update on Fixed-Duration Ibrutinib and Venetoclax for 1L CL…

Feat. A. Kater
05:52
ecancer

EHA 2021 Update on Blinatumomab for MRD-Positive B-Cell ALL

Feat. N. Short
05:42
ecancer

EHA 2021 Update on Blinatumomab + Ponatinib for Ph+ ALL: Interim Res…

Feat. N. Short
09:22
ecancer

EHA 2021 Update on KTE-X19, an Anti-CD19 CAR T-Cell Therapy for R/R …

Feat. B. Shah
05:28
ecancer

2020 ASH Update on IDH 1/2-Mutated AML: Does Ven+Aza vs. Aza Mono Im…

Feat. H. Kantarjian